In short
Clinical trials investigating MAGNESIUM ACETATE TETRAHYDRATE are studying how this substance is used in research settings and which patients may be included. The available trial data focus on treatment effects, safety-related outcomes, and patient groups such as people on hemodialysis or with other serious medical conditions.
Key points
- Only two authorised Phase 3 trials are listed in the provided data. One study looks at muscle protein turnover in chronic hemodialysis patients, with a small enrollment of 20 people. The other study looks at critically ill patients with metabolic acidosis and acute kidney injury, with 660 participants. The main outcomes are muscle protein synthesis in one trial and major kidney events at 90 days in the other. The data do not show a direct trial focused on MAGNESIUM ACETATE TETRAHYDRATE itself, so the available information is limited to the study records provided.
Trials overview
The provided trial data include two interventional studies, which means the researchers are testing a treatment and then measuring the results in patients.
Both studies are Phase 3 and are marked as authorised.
The records focus on serious medical situations, including chronic hemodialysis and critical illness with kidney problems.
Study 1: LOTUS
The first trial is called LOTUS and has the ID 2025-522111-42-02.
It is a Phase 3 interventional study with an enrollment of 20 participants.
The study is being done in people with chronic hemodialysis, which means patients whose blood is regularly cleaned by a dialysis machine because their kidneys do not work well enough.
The brief summary says the study aims to see the effect of IDPN on muscle protein synthesis in chronic hemodialysis patients and to describe the hemodynamic effects of IDPN.
The main endpoint is the difference in myofibrillar fractional synthetic rate during one week of treatment with IDPN versus control.
Study 2: Kidney outcomes in critical illness
The second trial has the ID 2025-523914-10-00 and is also a Phase 3 interventional study.
It includes 660 participants and focuses on metabolic acidosis, critical illness, and acute kidney injury.
The brief summary says the study is investigating the effect of sodium bicarbonate on major adverse kidney events at day 90.
The primary outcome is MAKE90, a combined endpoint that includes death, any kidney replacement therapy within 90 days after randomization, or persistent renal dysfunction at day 90.
The intervention list includes several infusion solutions and sodium hydrogen carbonate, which shows that this study compares treatment options given by intravenous infusion.
What the endpoints mean
An endpoint is the main result researchers measure to see whether a treatment helps.
In the LOTUS study, the endpoint measures how fast muscle protein is being made, which helps researchers understand muscle building in dialysis patients.
In the kidney study, the endpoint combines several serious outcomes into one measure so researchers can see whether treatment lowers the risk of major kidney problems.
Who the trials are for
The LOTUS trial is for people on chronic hemodialysis, a group that often has complex nutrition and muscle health needs.
The second trial is for critically ill patients who have metabolic acidosis and acute kidney injury, which are both serious conditions seen in hospitals.
These trial records do not provide full eligibility rules, so the exact inclusion and exclusion criteria are not shown in the source data.
What patients should know
The available records show that the research is still in the testing stage and is focused on specific patient groups rather than the general population.
The data do not give detailed results yet, so these entries describe what the studies are designed to measure, not what they have already found.
Because the source data are limited, the article can only summarize the trial aims, phases, populations, and endpoints that are listed here.